Pharma news
Americas
Case looked at whether generic treatment infringes ‘fridge temperature limitation method’ | Ruling underscores importance of clear labelling in drug patent infringement suits. 24 April 2025
Americas
With a career spanning an iconic consumer brand and big pharma, INTA's current president is focused on amplifying the voice of in-house counsel, finds Muireann Bolger. 22 April 2025
Americas
The bipartisan legislative push could create big hurdles for drug development, with concerns mounting over limited patent protections and increased litigation risks, hears Marisa Woutersen. 17 April 2025
Pharma
Massachusetts lawsuit claims subsidiary of UK pharma company unlawfully re-patented eculizumab, resulting in overpayments of more than $2 billion. 17 April 2025
Americas
Texas company launches sweeping lawsuits against five major players, alleging infringement of medical device patents tied to legacy Sanofi-Aventis technologies | Cases put billions in revenue and key drug delivery products in the spotlight. 14 April 2025
Pharma
Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC. 10 April 2025
Europe
The Düsseldorf court’s decision offers an instructive perspective on the legal nature of patent pledges as well as a reminder that it is risky to rely solely on informal public declarations, say Ina vom Feld and Maximilian Kücking of Herbert Smith Freehills. 10 April 2025
Americas
The IP specialist bypassed vendors and turned to its own ‘tech geeks’ to create an in-house AI solution for drafting patent applications. LSIPR meets the attorney coders doing it for themselves. 3 April 2025
Americas
Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing competition and patent expiration increase urgency for Lilly | New Jersey and Delaware stores accused of selling unapproved tirzepatide-based products. 3 April 2025
Americas
MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen. 1 April 2025